Related references
Note: Only part of the references are listed.A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer
Shane Stegeman et al.
ENDOCRINE-RELATED CANCER (2015)
Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon
Liv B. Gansmo et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
Kristen S. Purrington et al.
CARCINOGENESIS (2014)
The Functional TP53 rs1042522 and MDM4 rs4245739 Genetic Variants Contribute to Non-Hodgkin Lymphoma Risk
Chuanbo Fan et al.
PLOS ONE (2014)
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)
Stian Knappskog et al.
ONCOTARGET (2014)
Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility
Jibing Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Genetic Susceptibility to Triple-Negative Breast Cancer
Kristen N. Stevens et al.
CANCER RESEARCH (2013)
Genome-wide association studies identify four ER negative-specific breast cancer risk loci
Montserrat Garcia-Closas et al.
NATURE GENETICS (2013)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
Rosalind A. Eeles et al.
NATURE GENETICS (2013)
Association of a Genetic Variation in a miR-191 Binding Site in MDM4 with Risk of Esophageal Squamous Cell Carcinoma
Liqing Zhou et al.
PLOS ONE (2013)
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer
Stian Knappskog et al.
EUROPEAN JOURNAL OF CANCER (2012)
An integrated map of genetic variation from 1,092 human genomes
David M. Altshuler et al.
NATURE (2012)
MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk
Stian Knappskog et al.
PLOS ONE (2012)
The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
Stian Knappskog et al.
CANCER CELL (2011)
MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination
Xinjiang Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis
Konstantinos P. Economopoulos et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
Jessika Wynendaele et al.
CANCER RESEARCH (2010)
Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4
Shunbin Xiong et al.
CANCER RESEARCH (2010)
p53-a Jack of all trades but master of none
Melissa R. Junttila et al.
NATURE REVIEWS CANCER (2009)
Cohort Profile: Cohort of Norway (CONOR)
Oyvind Naess et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2008)
MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility:: Evidence from 21 case-control studies
Zhibin Hu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity
Hidehiko Kawai et al.
CANCER RESEARCH (2007)
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target
Xin Han et al.
MODERN PATHOLOGY (2007)
Mdmx as an essential regulator of p53 activity
JC Marine et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity
D Danovi et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
LK Linares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target
MJ Riemenschneider et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Share Paper
